N-Demethyl-N-nitrosolevofloxacin
Abstract
1. Introduction
2. Results and Discussion
2.1. Synthesis
2.2. X-Ray Crystal Structure(s)
2.3. Electronic Spectroscopies
3. Materials and Methods
3.1. General
3.2. N-Demethyllevofloxacin (2)
3.3. N-Nitroso-N-demethyllevofloxacin (3)
3.4. X-Ray Characterization and Structure Solution
3.5. Electronic Spectroscopies
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
Abbreviations
| ICH | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
| NDSRI | Nitrosamine Drug Substance-Related Impurity |
| API | Active Pharmaceutical Ingredient |
| CYP | Cytochrome P450 |
| EMA | European Medicines Agency |
| CPCA | Carcinogenic Potency Categorization Approach |
| FDA | Food and Drug Administration |
| MRM | Multiple Reaction Monitoring |
| DMSO | Dimethylsulfoxide |
| XRPD | X-Ray Powder Diffraction |
References
- Thresher, A.; Foster, R.; Ponting, D.J.; Stalford, S.A.; Tennant, R.E.; Thomas, R. Are All Nitrosamines Concerning? A Review of Mutagenicity and Carcinogenicity Data. Regul. Toxicol. Pharmacol. 2020, 116, 104749. [Google Scholar] [CrossRef] [PubMed]
- Nudelman, R.; Kocks, G.; Mouton, B.; Ponting, D.J.; Schlingemann, J.; Simon, S.; Smith, G.F.; Teasdale, A.; Werner, A.L. The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny. Org. Process Res. Dev. 2023, 27, 1719–1735. [Google Scholar] [CrossRef]
- Kruhlak, N.L.; Schmidt, M.; Froetschl, R.; Graber, S.; Haas, B.; Horne, I.; Horne, S.; King, S.T.; Koval, I.A.; Kumaran, G.; et al. Determining Recommended Acceptable Intake Limits for N-Nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach (CPCA). Regul. Toxicol. Pharmacol. 2024, 150, 105640. [Google Scholar] [CrossRef] [PubMed]
- Vogel, M.; Escher, S.E.; Weiler, E.; Londenberg, A.; Deppenmeier, U.; Whomsley, R. Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship Analysis. Drug Test. Anal. 2025, 17, 1772–1784. [Google Scholar] [CrossRef] [PubMed]
- Anderson, V.R.; Perry, C.M. Levofloxacin. Drugs 2012, 68, 535–565. [Google Scholar] [CrossRef] [PubMed]
- Wimer, S.M.; Schoonover, L.; Garrison, M.W. Levofloxacin: A Therapeutic Review. Clin. Ther. 1998, 20, 1049–1070. [Google Scholar] [CrossRef] [PubMed]
- Groom, C.R.; Bruno, I.J.; Lightfoot, M.P.; Ward, S.C. The Cambridge Structural Database. Acta Crystallogr. B Struct. Sci. Cryst. Eng. Mater. 2016, 72, 171–179. [Google Scholar] [CrossRef] [PubMed]
- Kasha, M. Characterization of Electronic Transitions in Complex Molecules. Discuss. Faraday Soc. 1950, 9, 14–19. [Google Scholar] [CrossRef]
- Perez, N.; Olmo, F.; Nuñez-Marinero, P.; Romay, L.; Colina, A.; Javier del Campo, F.; Heras, A. Levofloxacin Determination in Urine by Photoluminescence Spectroelectrochemistry. Electrochim. Acta 2025, 539, 147123. [Google Scholar] [CrossRef]
- Matchette, L.S.; Agrawal, A.; Pfefer, T.J. Fluoroquinolone Antibiotics Having the Potential to Interfere with Fluorescence-Based Diagnosis. Photochem. Photobiol. 2007, 83, 1386–1393. [Google Scholar] [CrossRef] [PubMed]
- Thakur, R.; Mallick, A.; Chakraborty, A. Photophysical and Photodynamical Study of Fluoroquinolone Drug Molecule in Bile Salt Aggregates. Photochem. Photobiol. 2012, 88, 1248–1255. [Google Scholar] [CrossRef] [PubMed]
- Altomare, A.; Cuocci, C.; Giacovazzo, C.; Moliterni, A.; Rizzi, R.; Corriero, N.; Falcicchio, A. EXPO2013: A Kit of Tools for Phasing Crystal Structures from Powder Data. J. Appl. Crystallogr. 2013, 46, 1231–1235. [Google Scholar] [CrossRef]
- Altomare, A.; Campi, G.; Cuocci, C.; Eriksson, L.; Giacovazzo, C.; Moliterni, A.; Rizzi, R.; Werner, P.E. Advances in Powder Diffraction Pattern Indexing: N-TREOR09. J. Appl. Crystallogr. 2009, 42, 768–775. [Google Scholar] [CrossRef]
- CrysAlis PRO, version 44.85; Agilent Technologies Ltd.: Yarnton, Oxfordshire, UK, 2014.
- Sheldrick, G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. A Found. Adv. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
- Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341. [Google Scholar] [CrossRef]
- MacRae, C.F.; Sovago, I.; Cottrell, S.J.; Galek, P.T.A.; McCabe, P.; Pidcock, E.; Platings, M.; Shields, G.P.; Stevens, J.S.; Towler, M.; et al. Mercury 4.0: From Visualization to Analysis, Design and Prediction. J. Appl. Crystallogr. 2020, 53, 226–235. [Google Scholar] [CrossRef] [PubMed]






| Compound | 3α | 3β |
|---|---|---|
| Empirical formula | C17H17FN4O5 | C17H17FN4O5 |
| Formula weight | 376.342 g mol−1 | 376.342 g mol−1 |
| Temperature | 298(2)K | 298(2)K |
| Wavelength | 1.54059Å | 0.71073Å |
| Crystal system | Monoclinic | Monoclinic |
| Space group | P21 (4) | C2 (5) |
| Unit-cell dimension | a = 13.145(6)Å | a = 17.515(9)Å |
| b = 6.949(2)Å | b = 7.116(3)Å | |
| c = 9.890(3)Å | c = 17.524(8)Å | |
| β = 111.64(2)° | β = 118.31(6)° | |
| Volume | 841.0(5)Å3 | 1922.7(9)Å3 |
| Z | 2 | 4 |
| Density (calculated) | 1.486 g cm−3 | 1.300 g cm−3 |
| Absorption coefficient | 1.011 mm−1 | 0.104 mm−1 |
| Crystal habit | Powder | Acicular |
| Theta range for data collection | 1.00–45.00° | 3.15–20.80° |
| Independent reflections | - | 1762 [Rint = 0.067] |
| Completeness to theta = 20.8° | - | 99.55% |
| Goodness-of-fit on F2 | - | 1.1224 |
| Final R indices | Rietveld: | [I > 2σ (I)]: |
| R1 = 0.1220 | ||
| wR2 = 0.2957 | ||
| R = 0.07657 | ||
| Rwp = 0.11371 | All data: | |
| R1 = 0.1754 | ||
| wR2 = 0.3496 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Maestri, C.; Lopresti, M.; Miletto, I.; Benyei, A.; Petreti, M.; Zangirolami, L.; Cavallotti, C.; Giovenzana, G.B. N-Demethyl-N-nitrosolevofloxacin. Molbank 2026, 2026, M2211. https://doi.org/10.3390/M2211
Maestri C, Lopresti M, Miletto I, Benyei A, Petreti M, Zangirolami L, Cavallotti C, Giovenzana GB. N-Demethyl-N-nitrosolevofloxacin. Molbank. 2026; 2026(4):M2211. https://doi.org/10.3390/M2211
Chicago/Turabian StyleMaestri, Claudio, Mattia Lopresti, Ivana Miletto, Attila Benyei, Marzia Petreti, Luisa Zangirolami, Camilla Cavallotti, and Giovanni B. Giovenzana. 2026. "N-Demethyl-N-nitrosolevofloxacin" Molbank 2026, no. 4: M2211. https://doi.org/10.3390/M2211
APA StyleMaestri, C., Lopresti, M., Miletto, I., Benyei, A., Petreti, M., Zangirolami, L., Cavallotti, C., & Giovenzana, G. B. (2026). N-Demethyl-N-nitrosolevofloxacin. Molbank, 2026(4), M2211. https://doi.org/10.3390/M2211

